<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Presenter</th>
</tr>
</thead>
</table>
| 8:00 a.m. | Welcome                                                                | Jennifer Dill, BS, CCRP  
Alliance Clinical Research Professionals Chair  
Heartland NCORP |
| 8:00 a.m. | A041501 A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL | Daniel DeAngelo, MD, PhD  
A041501 Study Chair  
Dana-Farber Cancer Institute  
Boston, MA |
| 8:40 a.m. | A031801 A Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients with Advanced Renal Cell Carcinoma with Bone Metastasis (RadiCal) | Rana Mckay, MD  
A031801 Study Chair  
University of California San Diego  
LaJolla, CA |
| 9:20 a.m. | A081801 Intensified adjuvant therapy for resected NSCLC: ALCHEMIST chemo-IO | Jacob Sands  
A081801 Study Chair  
Dana-Farber Cancer Institute  
Boston, MA |